During the inspection, the facility received 10 observations
Dr Reddy’s Laboratories notified stock exchanges that its formulations manufacturing facility (FTO-3) in Bachupally, Hyderabad, has been issued an Establishment Inspection Report (EIR) by the US Food and Drug Administration following an inspection conducted in October 2023.
According to Dr Reddy’s, the USFDA has categorised the inspection outcome as Voluntary Action Indicated (VAI). During the inspection, the facility received 10 observations.
- Advertisement -